NCT04671069已完成1 期
A Single Center, Open-Label, Drug Interaction Study of MGL-3196 With Clopidogrel in Healthy Subjects
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 20
- 试验地点
- 1
- 主要终点
- AUC from the time of dosing of clopidogrel as affected by single and multiple daily dosing with MGL-3196 100 mg/day in healthy subjects
研究概览
简要总结
The purpose of this study is to determine whether the single and multiple-dose pharmacokinetics (PK) of MGL-3196 are affected by co-administration with clopidogrel in healthy subjects.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Must be willing and able to provide written informed consent
- •Healthy, non-smoking male or female between the ages of 18 and 55 years (inclusive)
- •Body weight > 50 kg and BMI between 18 and 32 kg/m2 (inclusive)
- •Female subjects must:
- •Be non-pregnant and non-lactating
- •For females of non-childbearing potential, female must have undergone one of the following sterilization procedures at least 6 months prior to first dosing: hysterscopic fertilization bilateral salpingectomy, tubal occlusion, hysterectomy, bilateral oophorectomy
- •For postmenopausal women, are considered postmenopausal if amenorrheic for at least 12 months without an alternative medical cause
- •For females of childbearing potential, must one of the following birth control methods: surgical sterilization of partner, hormonal contraceptives no prone to drug-drug interactions, hormonal oral contraceptive agents such as normal and low dose combined pills or progesterone only pills, physical barrier method (eg, male condom) in addition to spermicide, non-hormonal intrauterine device for at least 3 months prior to first dosing, total abstinence from sexual intercourse for at least 3 months prior to first dosing and through study completion
- •If male and non-vasectomized, must agree to use a condom with spermicide or abstain from sexual intercourse from the first dose of study drug until 14 days beyond the last dose of study drug. No restrictions required for vasectomized male provided his vasectomy has been performed 3 months or more prior to Day
- •A male who has been vasectomized less than 3 months prior to study start must follow the same procedure as a non-vasectomized male.
排除标准
- •Any clinically significant abnormal findings on physical examination, clinical laboratory tests or 12-lead ECG.
- •Evidence or history of clinically significant hematological, endocrine, pulmonary, gastrointestinal, cardiovascular, renal, hepatic, neurological or psychiatric disease.
- •Current or recent (< 6 months) hepatobiliary disease; or AST, ALT or direct bilirubin greater than the upper limit of reference range at screening. Repeat testing is allowed per site standard procedures.
- •Gilbert's syndrome.
- •Pre-existing condition interfering with normal gastrointestinal anatomy or motility, hepatic and/or renal function that could interfere with the absorption, metabolism, and/or excretion of study drug (Cholecystectomy is allowed).
- •Abnormal screening ECG: including machine-read QTcF >450 msec in men and QTcF > 470 msec in women (confirmed by manual over read) or any rhythm other than normal sinus rhythm which is interpreted by the Investigator to be clinically significant.
- •History of sensitivity to a similar study drug, thyroid medication, or a history of important drug or other allergy (except for untreated, asymptomatic seasonal allergies at time of dosing) unless deemed not clinically significant by the Investigator.
- •Participation in another clinical trial of an investigational drug (or medical device) within the last 30 days prior to the Day 1, or who have been exposed to more than four new chemical entities within 12 months prior to Day 1.
研究组 & 干预措施
MGL-3196 100 mg tablet plus Clopidogrel 75 mg tablet
Experimental
干预措施: MGL-3196 (Drug)
MGL-3196 100 mg tablet plus Clopidogrel 75 mg tablet
Experimental
干预措施: Clopidogrel (Drug)
结局指标
主要结局
AUC from the time of dosing of clopidogrel as affected by single and multiple daily dosing with MGL-3196 100 mg/day in healthy subjects
时间窗: 14 days
Pharmacokinetics (Cmax) of clopidogrel as affected by chronic dosing with MGL-3196 100 mg/day in healthy subjects
时间窗: 14 days
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
1 期
Study to Evaluate Drug-Drug Interaction of DWP16001 in Combination With DWC202001 and DWC202002 in Healthy Male AdultsHealthyNCT04343547Daewoong Pharmaceutical Co. LTD.34
已完成
3 期
Pharmacokinetic, Pharmacodynamic, Safety, and Efficacy Study of Rivaroxaban for Thromboprophylaxis in Pediatric Participants 2 to 8 Years of Age After the Fontan ProcedureThrombosisNCT02846532Janssen Research & Development, LLC112
已完成
2 期
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Cefiderocol in Hospitalized Neonates and InfantsGram-Negative Bacterial InfectionsNCT06086626Shionogi30
已完成
1 期
PK and PD Study of Natalizumab in Pediatric Subjects With RRMSRelapsing-Remitting Multiple SclerosisNCT01884935Biogen13
已完成
1 期
A Multiple-Dose, Open-Label, Phase 1, Pharmacokinetic, Pharmacodynamic, and Safety Study of Avonex® in Chinese Healthy Volunteer SubjectsHealthyNCT01416207Biogen24